证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 编号：2015-002 | --- | --- | --- | |----------------|----------------------------|---------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 景顺投资（杨慧妍）、瑞士银行（孙裕文）、上海保银投资(陈 | | 人员姓名 | 华)、 | Marshall Wave Asia limited （谢婧）、景林资产（张 | | | | 小刚）、嘉实基金（王丹）、凯思博投资（王士振）、挪威银 | | | | 行（钱风奇）、法国巴黎投资管理亚洲有限公司（梁珮雯）、 | | | | 高盛（叶霖）、西南证券（周平）、安本 ...

编号：2014-003 投资者关系活动 √特定对象调研 □分析师会议 类别 □媒体采访 □业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他 （请文字说明其他活动内容） 证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 | --- | --- | |----------------|----------------------------------------------------------| | | | | 参与单位名称及 | 方正证券（崔文亮、刘亚明、蒋一樊）、国信证券（吕科、杨 | | 人员姓名 | 辉）、合众资产（庞兴华、金妍）、光大证券（曾宪钊）、博颐 | | | 投资（任晓燕、徐大成）、银河基金（王海平）、沃胜资产 | | | （吴汉靓）、华泰证券（向晖）、博时基金（王俊杰）、鹏华 | | | 基金（于博、吴印）、安邦资产（高远、田文奇）、信诚人寿 | | | （林柏川）、富邦基金（高松）、国泰基金（陈辞行）、光大 | | | 证券（胡银玉）、源乘投资（邬安沙）、犇腾投资（郭瀚 | | | 华）、华西证券（祝佳婧）、尚雅投资（汪新文）、新华资产 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 编号：2015-001 | --- | --- | --- | --- | --- | --- | --- | --- | |----------------|--------------------------|------------------------------------------------------|-------|-------|-------|--------------------------------------------------------|-------| | | | | | | | | | | 投资者关系活动 | √ 特定对象调研 | □分析师会议 | | | | | | | 类别 | □ | 媒体采访 □业绩说明会 | | | | | | | | □新闻发布会 □路演活动 | | | | | | | | | □ 现场参观 | | | | | | | | | □ 其他 | （请文字说明其他活动内容） | | | | | | | 参与单位名称及 | | | | | | 盈泰明道基 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 编号：2020-001 | --- | --- | --- | |-------------------|---------------------------------|----------------------------------------------------| | | R 特定对象调研 | □ 分析师会议 | | | □ 媒体采访 | □ 业绩说明会 | | 投 资 者 关 系 活 | □ 新闻发布会 | □ 路演活动 | | 动类别 | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | | | 天风证券股份有限公司、西南证券股份有限公司、中泰证 | | | | 券股份有限公司、川财证券有限责任公司、光大证券股份 | | | | 有限公司、安信证券股份有限公司、国泰君安证券股份有 | | | | 限公司、银华基金管理股份有限公司、上海槐南资产管理 | | | | 有限公司、广州中羲资产管理有限公司、西藏文储投资基 | | 参 与 单 位 名 称 | | 金管理有限公司、北 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司投资者关系活动记录表 编号：2018-001 | --- | --- | --- | |----------------|--------------------------------|------------------------------------------------------| | | | | | 投资者关系活动 | √ 特定对象调研 | □ 分析师会议 | | 类别 | □ 媒体采访 | □ 业绩说明会 | | | □ 新闻发布会 | □ 路演活动 | | | □ 现场参观 | | | | □ | 其他 （请文字说明其他活动内容） | | 参与单位名称及 | | 天风证券（杨烨辉）、西南证券（周平） | | 人员姓名 | | | | 时间 | 2018 年 6 月 26 日 | | | 地点 | 公司会议室 | | | 上市公司接待人 | | 董事长、总经理邱宇先生；副董事长冷雪峰先生；财务总监 | | 员姓名 | 赖文女士；董事会秘书崔丹先生。 | | | 投资者关系活动 | 1 、公司经营情况介绍 | | | 主要内 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司 投资者交流电话会议纪要 | --- | --- | --- | --- | |-----------------------|----------------------------------|------------------------------------------|-----------------------------------------------------------------------------------------------------------| | \n投资者关系活动 | | | 编号： 2021-002 | | 类别 | □ 特定对象调研 | □ 分析师会议 | | | | □ 媒体采访 □ | 业绩说明会 | | | | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | ■ 其他：电话会议 | | | | 参与单位名称及 | | | 天风证券股份有限公司、西南证券股份有限公司、中信证券 | | 人员姓名 | | | 股份有限公司、中银国际证券股份有限公司 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司 投资者交流电话会议纪要 编号：2021-001 | --- | --- | --- | --- | |----------------|------------------------------|--------------------------------------------------------|-------------------------------------| | | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | | □ 新闻发布会 □ | 路演活动 | | | | □ 现场参观 | | | | | ■ 其他：电话会议 | | | | 参与单位名称及 | | 天风证券股份有限公司、西南证券股份有限公司、中信证券 | | | 人员姓名 | | 股份有限公司、中银国际证券股份有限公司、东方证券股份 | | | | | 有限公司、方正证券股份有限公司、国泰君安证券股份有限 | | | | | 公司、恒泰证券股份有限公司、招商基 ...

证券代码：300006 证券简称：莱美药业 重庆莱美药业股份有限公司 投资者关系活动记录表 编号：2021-005 | --- | --- | --- | --- | --- | |----------------|-----------------------------------------------------|-----------------------------------------------------------------------------------------------------------|------------------------------|------------| | | | | | | | 投资者关系活动 | □ 特定对象调研 | □ 分析师会议 | | | | 类别 | □ 媒体采访 □ | 业绩说明会 | | | | | □ 新闻发布会 | ■ 路演活动 | | | | | □ 现场参观 | | | | | | □ 其他 | | | | | 参与单位名称及 | | 长城证券股份有限公司、中泰证券股份有限公司、渤海证券 | | | | 人员姓名 | ...

Financial Performance - The company's revenue for Q3 2022 was ¥264,421,982.22, a decrease of 5.47% compared to the same period last year, and a total revenue of ¥670,853,551.45 for the year-to-date, down 24.77%[4] - The net profit attributable to shareholders for Q3 2022 was ¥11,698,716.60, while the year-to-date net profit was -¥37,373,010.95, reflecting a significant decline of 287.15%[4] - The basic earnings per share for Q3 2022 was ¥0.0111, compared to -¥0.0354 for the same period last year, indicating a decrease of 272.68%[4] - Total operating revenue for the third quarter was ¥670,853,551.45, a decrease of 24.7% compared to ¥891,700,644.80 in the same period last year[23] - The company reported an operating loss of ¥66,999,884.21, compared to an operating profit of ¥25,717,051.29 in the previous year[23] - Net profit for the period was a loss of ¥46,070,929.86, contrasting with a profit of ¥25,413,513.35 in the same quarter last year[23] - The net profit for the third quarter of 2022 was -44,728,469.91 CNY, compared to a net profit of 16,959,509.20 CNY in the same period last year, indicating a significant decline[24] - The company reported a basic and diluted earnings per share of -0.0354 CNY, compared to 0.0205 CNY in the same period last year[24] Assets and Liabilities - The company's total assets at the end of Q3 2022 were ¥3,037,979,049.22, an increase of 3.80% from the end of the previous year[4] - Total assets reached ¥3,037,979,049.22, up from ¥2,926,773,933.76, indicating a growth of 3.8%[21] - The company’s total liabilities increased to ¥833,343,198.44, compared to ¥714,647,217.06, reflecting a rise of 16.6%[21] - The company’s total current assets increased to ¥1,795,368,277.29 from ¥1,726,995,266.10, a growth of 3.9%[20] Cash Flow - Cash flow from operating activities for the year-to-date was -¥26,539,836.25, a decline of 140.08% compared to the previous year[11] - The operating cash flow for the period was -26,539,836.25 CNY, a decrease from 66,213,762.66 CNY in the previous year, reflecting a negative cash flow situation[27] - The total cash inflow from operating activities was 1,071,511,372.34 CNY, down from 1,266,731,649.78 CNY year-over-year, indicating a decrease of about 15.4%[27] - The total cash outflow from operating activities was 1,098,051,208.59 CNY, a decrease from 1,200,517,887.12 CNY in the previous year[27] - The company reported a cash and cash equivalents balance of 686,921,451.70 CNY at the end of the period, an increase from 617,860,422.49 CNY at the end of the previous year[28] - Cash and cash equivalents increased to ¥738,378,951.70 from ¥559,430,726.55, representing a growth of 32.0%[20] - The net cash flow from financing activities was 177,280,866.53 CNY, compared to 135,025,164.38 CNY in the same period last year, showing an increase of approximately 31.4%[28] - The company received 351,999,999.00 CNY in borrowings during the period, a significant increase from 91,000,000.00 CNY in the previous year[28] Investments and Acquisitions - The company reported a significant increase in long-term equity investments by 45.80%, totaling ¥136,649,586.16, due to increased external investments[8] - Long-term equity investments rose to ¥136,649,586.16 from ¥93,724,606.83, marking an increase of 46.0%[20] - The company acquired all tangible and intangible assets related to the injection of Triptorelin Acetate from Hainan Shuangcheng Pharmaceutical Co., Ltd. for RMB 28.8 million[15] - The company is actively involved in strategic partnerships and acquisitions to enhance its market position and product portfolio[15] Regulatory Approvals - The company received drug registration certificates for two specifications of Esomeprazole Magnesium Enteric-coated Capsules (20mg and 40mg) from the National Medical Products Administration[16] - The company received approval for two specifications of Tranexamic Acid Injection (5ml: 0.25g and 5ml: 0.5g) after passing the consistency evaluation of generic drug quality and efficacy[16] - The company received approval for the injection of Fludarabine Phosphate (50mg) after passing the consistency evaluation of generic drug quality and efficacy[17] - The company has received various approvals for its pharmaceutical products, indicating ongoing expansion in its product offerings[16][17] Legal Matters - The company recognized a net loss of RMB 35,377,357.50 based on a first-instance judgment regarding a lawsuit related to the exclusive sales agency rights of Tadalafil[17] - The second-instance judgment of the lawsuit resulted in an impact of RMB 21 million on the company's non-operating income for the current period[17] Research and Development - Research and development expenses for the quarter were ¥54,423,054.23, slightly up from ¥51,915,525.42, indicating a focus on innovation[23] Shareholder Information - The company has a total of 128,700,000 shares held by Qiu Yu, representing a significant portion of its equity[19]